Author

Daozheng Xu

Observed names: Dao-Zheng Xu, DaoZheng Xu

Observed institutions: Bristol-Myers Squibb (United States), Beijing Ditan Hospital

OpenAlex ID: A5111733129

Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China

2008 · Guangbi Yao, Chengwei Chen, et al. · Hepatology International · 45

Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China

2007 · Guangbi Yao, Chengwei Chen, et al. · Hepatology International · 41

Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B: a randomized, multicenter study

2008 · Guangbi Yao, ChengWei Chen, et al. · Hepatology International · 25

Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B

2015 · Jin-Lin Hou, Daozheng Xu, et al. · Advances in Therapy · 22

Entecavir for the treatment of lamivudine-refractory chronic hepatitis B patients in China

2007 · Guangbi Yao, Xiaqiu Zhou, et al. · Hepatology International · 15

Utility of the Apparent Diffusion Coefficient Value in Differentiating Gallbladder Cancer from Chronic Cholecystitis with Wall Thickening

2018 · Tong-Hua Zhang, Jian-Xin Chen, et al. · Journal of Medical Imaging and Health Informatics · 1

Works count: 6

Citation count: 149

H-index: 5

I10-index: 5